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NOMENCLATURE
MMS Mohs Micrographic Surgery
NMSC Nonmelanoma skin cancer
BCC Basal cell carcinoma
SCC Squamous cell carcinoma
k Number of patients scheduled
pns Patient no-show probability
pr Patient re-entrant probability
β Patient re-entrant probability shape coeffecient
r Revenue from single service
cw Hourly waiting cost
cO Hourly overtime cost
Si Patient schedule for slot i
Xi Number of scheduled patients who arrive for slot i
Zi Number of patients who re-enter the system in slot i following
treatment in slot i− 1
Li Number of patients treated in slot i provided the queue is long
enough
Yi Number of patients who overflow from slot i into slot i− 1
Ti Number of patients treated in slot i
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ABSTRACT
Steidle, Stephen V. M.S.I.E., Purdue University, May 2013. Scheduling in Mohs
Micrographic Surgery Clinics. Major Professors: Mark Lawley and Seokcheon Lee.
Mohs Micrographic Surgery (MMS) is a surgical method used for the excision of
aggressive skin cancers in areas of high cosmetic importance, such as the face and
hands. The practice has been gaining popularity worldwide for its low recurrence
rates and cosmetic results. Current clinics though are plagued by extreme wait times
and an overall poor patient experience. In this paper we look to explore this prob-
lem by applying systems engineering principles including optimization and scheduling
with the goal of improving the patient experience. Currently, little literature exists
exploring the difficulties associated with scheduling for MMS clinics which primar-
ily revolve around patient recirculation for an unknown number of repetitions with
little predictive ability. By developing a simulation model depicting current clinic op-
erations, we have explored the current practice of clinics through several important
performance measures while being able to determine an optimal number of patients to
be scheduled. We have also explored the impact of changing re-entrant probability on
the nature of the patient schedules. We have developed a set of qualitative scheduling
constraints for on-the-fly physician application and a sequential scheduling policy to
produce myopically optimal patient schedules for maximizing the patient experience.
11. INTRODUCTION
Skin cancer affects millions of Americans each year, with over 3.5 million cases being
diagnosed in at least 2 million patients every year [1]. Of these occurrences, non-
melanoma skin cancers (NMSC) are the most significant, including basal cell carci-
noma (BCC) and squamous cell carcinoma (SCC), each accounting for an estimated
2.8 million and 700,000 cases a year, respectively [2]. Mohs Micrographic Surgery
(MMS) is a technique used in the treatment of NMSCs. MMS has several advan-
tages over other treatments, including being the leader in cost-effectiveness [3], low
recurrence rates [4], and less permanent cosmetic damage [5]. However, one of the
well-known disadvantages to MMS is long time the procedure can take to complete,
often resulting in patients spending entire days at the clinic [7].
In a standard MMS clinic setting, the physician begins by identifying the visible
margins of the tumor in question. After identification, the physician applies local
anesthesia and makes his first incision, cutting at between 30◦ and 45◦. The sample
is then sent to a pathologist for analysis. Typically when examining the tissue margins
for signs of cancer, pathologists use a method known as the bread-loaf technique. This
method reviews less than 1% of the overall margins [6]. However, in MMS nearly 100%
of the margin is examined, enabling the pathologist to identify clear margins much
more reliably [7]. However, the trade off for 100% margin clearance, as previously
mentioned, is the long and tedious process that is MMS [8]. Usually, multiple excisions
are required to achieve clear margins. The typical method of patient flow through this
system is as follows. A patient sees the physician for initial tumor identification and
first round of excision. Following the first excision, the patient returns to the waiting
room to wait for the pathology report to be completed. The returning pathology
report will have one of two possible results: clear or unclear margins. Clear margins
2mean that the margins of the excised area are cancer free and the patient requires
no more excisions. Unclear margins indicate that the margins still contained cancer
cells and addition excision is required. If the patient has clear margins, then he or
she returns to the physician for wound repair. This rotation through physician and
pathology service continues until the patient’s margins are determined to be clear
and wound repair has been conducted. This process is demonstrated in Figure 1.1
(Reprinted with permission. Copyright 2013 University of Wisconsin Hospitals and
Clinics Authority. [9]).
Figure 1.1.: The Mohs Surgery Process [9]
1.1 Objectives
When considering this problem from a scheduling perspective, it is the rotational
aspect of the patient’s progress through the system that defines our problem. Sev-
eral examples in literature exist examining scheduling problems featuring recircula-
tion [10, 11], and scheduling in healthcare scenarios is also a very heavily researched
area [12,13] . However, what differentiates our problem from other examples in litera-
ture is the stochastic nature of the amount of recirculation. When scheduling patients
into this system, it is difficult, if not impossible, to know precisely how many repe-
titions a patient will require to complete treatment. This detrimental characteristic
3of our system can lead to poorly structured schedules causing excessive bottleneck-
ing and patient wait time. Patients waiting to see the physician a second time are
delayed due to the availability of the pathologist or the physician is seeing another
patient. We hope to develop a multi-faceted approach to this problem. With the little
attention paid to MMS in scheduling and simulation literature, our first objective is
to lay a foundation by developing a simulation model of an MMS clinic. The devel-
opment and analysis of this model should lead to an increased understanding of how
this system operates. Our second objective is to develop a system of scheduling con-
straints and heuristics based on patient characteristics that would enable a physician
or individual responsible for scheduling able to make informed decisions about what
types of patients to schedule. Finally, our last objective is to develop an algorithmic
scheduling policy based on an objective function that takes into account not only the
clinic’s costs and revenues, but also the patient experience. By combining these three
objectives together, we can fulfill our overall goal of providing tools to improve clinic
operations while simultaneously improving the patient experience.
1.2 Organization
Chapter 1 outlines what MMS is and how it is used, as well as the objectives of this
research and why it is important to MMS clinics.
Chapter 2 presents a literature review of research into MMS as well as important
peripheral papers. It begins with a review of non-melanoma skin cancers and their
risk factors and symptoms. Next is a review of MMS and its implications. This is
followed by an analysis of the current literature directly related to MMS. Finally, a
review of relevant clinical scheduling policies is conducted.
Chapter 3 presents a simulation model of an MMS clinic. All relevant parameters and
aspects of the clinic are discussed. Additionally, an objective function is developed for
4optimizing clinic function in relation to operations and the patient experience. This
function is then analyzed and its behaviors under various conditions are discussed.
Chapter 4 delineates a method of generating random patients for scheduling in a
clinic and presents several sets of constraints and heuristics that could be used in an
MMS clinic. Each of these is identified in detail and explained. These heuristics are
then analyzed using a simulation model similar to that in the previous chapter. The
results of these simulation runs are then presented and analyzed.
Chapter 5 describes a sequential scheduling policy as an alternative to the heuris-
tic method presented in the previous chapter. An objective function similar to that
of Chapter 3 is utilized to schedule patients according to the policy presented. Initial
experimental results of this model are presented along side an analysis of its behavior.
Chapter 6 discusses the overall conclusions of this research as well as describing the
important contributions made by it. Future areas of research are also presented.
52. LITERATURE REVIEW
2.1 Overview of Non-melanoma Skin Cancers
Skin cancer is defined as a cluster of abnormal skin cells that grow uncontrollably.
Skin cancers are caused when DNA and RNA in skin are damaged by exposure to
ultraviolet radiation and these damages go unrepaired. These cancers can be broadly
grouped into two categories: melanoma and non-melanoma. Non-melanoma skin
cancers (NMSCs) include two primary subcategories, namely basal cell carcinomas
and squamous cell carcinomas. An additional wide variety of subtypes exists under
the umbrella of NMSC, but it is typically used to identify those two primary subtypes.
The various types of carcinomas are typically identified by the layer of the epidermis
in which they arise. Basal cell carcinomas are identified by the fact that they are
found in the topmost level of the skin, the epidermis, and squamous cell carcinomas
begin in the middle layer.
2.1.1 Risk Factors
The primary cause for all skin cancers is identified as over-exposure to ultraviolet
(UV) radiation. This is typically encountered through prolonged exposure to sun-
light or tanning beds. Additionally though, there are a combination of personal and
environmental risk factors that can increase an individuals susceptibility to NMSC.
The major personal factor that puts individuals at an increased risk for NMSC is
a susceptibility to UV radiation. Characteristics indicative of this typically include
light skin, hair or eye color [14]. Individuals who possess these characteristics and
who are over-exposed to UV radiation have an increased risk of developing NMSC
at some point during their lives. Environmental risk factors are primarily linked to
6geographic location. Areas nearer to the equator which typically have thinner ozones
and therefore increased penetration by UV radiation typically see increased rates of
NMSC than areas further from the equator [15].
2.1.2 Symptoms
Basal cell carcinomas and squamous cell carcinomas vary in their physical presen-
tations. Basal cell carcinoma presentations are typically divided into the following
clinical subtypes, but often include a mix of multiple [16].
• Classic rodent ulcer - a lesion on the surface of the skin with necrotic tissue in
the center
• Nodular or cystic - a small, translucent nodule on the skin through which ex-
posed blood vessels can be seen
• Superficial - an erythematous patch of skin, often difficult to differentiate from
other conditions such as eczema
• Morphoeic - a waxy scar made up of white sclerotic plaque
• Pigmented basal cell carcinoma - similar in appearance to a nodular or cystic
BCC, but with dramatically increased melanin levels
Squamous cell carcinomas are not as varied as basal cell carcinomas, but unlike BCCs,
they present with precursor lesions. As such, these precursor lesions are used to
identify an SCC. There are three primary types of precursor lesions with squamous
cell carcinomas [16].
• Actinic keratosis - a flat, crusty or scaled area that develops into a wart-like
surface
• Squamous-cell carcinoma in situ (also known as Bowen’s disease) - a clearly
defined erythematous plaque that increases in size and features a scaled or
crusted surface
7• Keratoacanthoma - a symmetrical dome-shaped skin inflammation with keratin
scales on its peak
While all three of these have been identified as precursor lesions for squamous cell
carcinomas, developing any of these does not guarantee a diagnosis of SCC.
2.2 Overview of Mohs Micrographic Surgery
Mohs Micrographic Surgery is a procedure that has been used for the past 70
years to treat skin cancer. Treatment methods started in 1938 by Frederic E. Mohs
with the utilization of a zinc chloride paste to fix the tumor in situ, so that as each
layer of the tumor was excised, the margins could be evaluated. However, this fixed
method had substantial drawbacks, including only being able to perform one layer
of excision per day and necrosis caused by the zinc chloride paste. In 1953, Mohs
performed several layers without the utilization of the chloride paste and saw success
in freezing the horizontal layers. This began the modern fresh tissue technique, which
enabled the surgeon to perform multiple layers as well as wound repair in a single
day [17]. Initially, only BCC and SCC were treated using Mohs surgery. However,
in the last 40 years, this procedure has gained significantly in not only popularity
but also application [5]. Beyond simply BCC and SCC, today MMS is used to treat
other tumor types such as verrucous carcinoma, extramammarry Paget disease, and
microcystic adnexal carcinoma [17].
The reasoning behind the utilization of MMS is that in most physical presen-
tations of skin cancer, the tumors grow contiguously but unpredictably. The ex-
ternal presentation and margins of the tumor may have little to do with the ac-
tual subcutaneous spread of the tumor. Typically, long finger-like extensions grow
outward from the central mass of the tumor. In order to avoid recurrence, which
can often be attributed to incomplete excision [18], Mohs attempts to completely
excise all cancer cells. MMS is able to identify these extensions though the exam-
ination of horizontal cross sections removed layer by layer by the physician. It is
8this type of analysis, in contrast to the standard “bread-loaf” technique used in
traditional tumor excision methodologies, that allows such accurate identification
of the tumors actual margins [7]. The difference between these two techniques is
demonstrated in Figures 2.1 and 2.2 (Images reprinted with permission from Med-
scape Reference (http://emedicine.medscape.com/), 2013, available at: http:
//emedicine.medscape.com/article/1125510-overview).
It is this technique that allows MMS to feature substantially lower recurrence rates
than other types of surgical excisions [4]. As such, MMS “remains the gold standard
for the surgical management of basal cell and squamous cell carcinomas” [7]. Not
only do these techniques offer much lower recurrence rates, but they also enable the
physician to conserve as much tissue as possible during the resection and eventual
wound closing. Because the physician is able to accurately identify the location of
any residual extensions, nodules, or tumor, areas that are unaffected are able to
be left intact [8]. This permits maximum effectiveness while minimizing cosmetic
damage. Since a substantial portion of BCC and SCC occur in areas of high cosmetic
significance, such as the face and hands, the use of Mohs is even more justified [19].
Much research has also been done into the cost-effectiveness of Mohs surgery
[19–23]. The problem with much of this literature is that MMS is performed under
various conditions by various types of professionals, leading to difficulty in compar-
isons. For example, the paper by Bialy only studies MMS procedures performed by
otolaryngologic (ENT) surgeons [20] while the analysis by Smeets is from a training
hospital [19]. With the wide variety of conditions under which Mohs is performed, a
consistent cost analysis can be difficult to obtain. A review published in 2009 reviews
all of these and many more in an attempt to determine the cost-effectiveness of Mohs
surgery [23]. It is their finding that when coupled with the decreased recurrence rates
and decreased cosmetic damage, Mohs is in fact a cost- effective treatment. In fact,
it is on average less than the overall cost of traditional excision, especially in light
of the recurrence rates for such procedures and the additional cost incurred when
undergoing a second procedure.
9Figure 2.1.: The Bread-Loaf Technique [17]
The most consistently cited drawback to Mohs surgery is the tediousness of the
process, for both the patient and the physician [24–27]. The duration of the procedure
as well as the repeated excisions can be difficult for a patient. This becomes even more
10
Figure 2.2.: The Mohs Technique [17]
problematic when the patient suffers from a debilitating condition such as dementia,
poor sphincter control or spinal arthritis. Some also deem the necessity of removing
all cancer cells to avoid recurrence questionable and cite the fact that even with this,
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recurrence does still occur in some Mohs cases. [4, 26]. While the procedure may
be long and difficult, most physicians still identify it as the best treatment option
available for patients [5, 23].
In summation, Mohs Micrographic Surgery has been identified as the best treat-
ment of choice when considering basal cell and squamous cell carcinomas. This pro-
cedure has dramatically decreased recurrence rates while enabling the physician to
conserve as much tissue as possible. This minimizes the cosmetic harm caused by
the procedure, which is exceptionally valuable since many BCC and SCC occur on
the face. Not only is this the best treatment option available, but it has also been
found to not only be cost-effective but also less costly than traditional excision meth-
ods. The primary drawback seen in Mohs is the tediousness and the length of the
procedure which can be burdensome on the patient.
2.3 Current Mohs Micrographic Surgery Literature
Little literature exists today studying the operational aspects of Mohs Micro-
graphic Surgery. Literature that does exist about Mohs is more focused on cost-
effectiveness, recurrence rates, and improvements to the procedure. Considering the
interesting nature of the operation of an MMS clinic, we find this lack of literature
surprising. To improve the current status of MMS clinics, we began by reviewing any
mention of Mohs, heuristics, or scheduling and only a single paper was found, The
Webb and Rivera (WAR) Score (from now on referred to as WAR Score) [28]. The
stated goal of this paper is to obtain an easily used preoperative tool that would en-
able a physician to ascertain the difficulty of and time required to complete an MMS
case. The data for this study was obtained through a questionnaire which inquired
about four preoperative characteristics (original lesion size biopsied, recurrent or not,
located on nose, eyelid, ear, or lip, and whether or not it is of an aggressive subtype)
and two post operative questions (number of stages required and time from first cut
to final suture or repair). Based on the answers to these questions, a statistical
12
analysis was completed to identify which characteristics were statistically significant
predictors of both the number layers and amount of time required to complete the
procedure. These predictors were then ranked and scored based on how significant
each was. Based on these rankings and scores, the WAR score was developed, with
higher scores being associated with more complex and longer duration surgeries. The
researchers found that the WAR score was significantly correlated to both the num-
ber of layers required and the overall surgery time. The most difficult aspect of this
problem was the lack of ability to accurately predict the difficulty of the procedure.
As mentioned previously, carcinomas such as those treated with Mohs surgery of-
ten feature extensions that can infiltrate far beyond the physical presentation of the
tumor. As such, the number of layers required can be very difficult to ascertain [29].
The need for a method of predicting the amount of subcutaneous spread of the
neoplasm is obvious. Two studies were found examining this and attempting to
develop methods to accomplish it. The primary source of literature in the area comes
from two sources by one individual, R. Sonia Batra, MD. Her two papers in this
area, Predictors of extensive subclinical spread in nonmelanoma skin cancer treated
with Mohs micrographic surgery (from now on referred to as Predictors) [30] and A
Risk Scale for Predicting Extensive Subclinical Spread of Nonmelanoma Skin Cancer
(from now on referred to as Risk Scale) [31] form the basis of the patient distribution
data used in this paper. Predictors [30] focuses primarily on identifying which patient
characteristics are indicative of a patient having extensive subclinical spread. Batra
uses five categories of characteristics: age, sex, carcinoma location, carcinoma size,
and carcinoma classification. A multivariate analysis is then conducted to identify
the most significant predictors, including single characteristics and combinations of
them. Her paper Risk Scale [31] conducts a similar experiment but offers an additional
point system for determining what level of risk a patient is at for extensive subclinical
spread. Using the predictors established in the previous paper, Batra assigns each one
a point value based on how strong of an indicator of extensive subclinical spread it is.
One characteristic about both of these papers to note is that Batra cites as a primary
13
weakness of both papers the fact that patients used in these studies were not general
NMSC patients, but ones whose carcinomas has been identified as particularly suited
to MMS. This actually causes the data used to be more suited to our uses, as we are
not considering the general population of NMSC sufferers, but only those who receive
MMS.
2.4 Scheduling for Outpatient Clinics
In order to tackle the problem of scheduling the clinics, a wide variety of healthcare
scheduling literature was reviewed. Gupta [13] and Cayirli’s [12] reviews provided ex-
cellent foundations for this work, and several examples of healthcare heuristics were
found [32, 33] . However, little of the literature existing in the field is strictly appli-
cable to this problem, due to the aforementioned re-entrant problem. Through our
initial analysis of these works, it was decided to pursue a specific variety of schedul-
ing procedure: a sequential, myopic policy that accounted for no-show probability. A
review of sequential scheduling methodologies yielded several results [34, 35]. Over-
booking models also yielded a pair of results [35, 36]. Turkcan’s 2011 paper [34]
presents a method for developing sequential clinical schedules utilizing specific ser-
vice criteria, such as maximum waiting and overtime. Muthuraman’s 2008 paper [36]
delineates of substantial model for overcoming patient no-show through overbooking.
A combination of these two can be used to produce a model for our clinics, after the
incorporation of the re-entrant problem.
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3. SIMULATION AND NUMERICAL ANALYSIS OF
CLINIC OPERATIONS
3.1 Simulation Model Development
Our first objective is to model how MMS clinics are currently operated, in order
to establish a baseline to which our other proposed solutions can be compared. The
model of current practice is based on the following assumptions.
1. Patients arrive individually in 30 minute intervals with k patients scheduled [13].
2. All patients have a no-show probability of pns = 0.1 [36].
3. The probability of re-entrance into the queue, pr, is a function of the number
of repetitions through the queue, n, and a shape coefficient, β of the form
pr(n, β) = e
−β(n−1). (3.1)
4. System has two stages, each with a single server [17].
5. Patients are punctual (arrive at start of appointment) [34].
The pr(n, β) function was defined in this manner to meet certain requirements for
the re-entrant probability. These requirements follow.
1. Patients must enter the system at least two times: excision and wound repair
[17].
2. The probability of a patient re-entering the queue should decrease with the
number of entrances.
3. We must be able to account for varying patient characteristics and physician
behaviors.
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The first requirement arises simply from the way patients flow in the system. A
patient cannot enter the system once and leave. This would be the same as a patient
receiving one cut from the physician and leaving. This is guaranteed by the (n − 1)
expression in the exponent. On the first visit, pr(1, β) = 1 regardless of the β value.
Our second requirement corresponds to the removal of additional layers. The more
times a patient re-enters the system, the more layers they will have removed. As
there is a limit amount of layers a physician can reasonably perform, usually between
two and six [30], we can assume that with increasing re-entrances, the probability
of re-entrance declines. This is confirmed by the negative value of the exponent.
Finally, different patients have different needs and different physicians have different
practices. In order to account for these, we wish to be able to control the shape of
the curve. We do this through β. Now, we can state these mathematically as follows.
1. pr(1, β) = 1 ∀ β
2. For a constant β, as n increases, pr(n, β) decreases
3. For n 6= 1, as β decreases, pr(n, β) increases
The first point is essential because we know that patients in this system must visit
the physician at least twice. After the first visit the patient must re-enter at least
once. This is guaranteed since the probability of re-entrance after the first visit is 1.
The second point indicates that the more a patient re-enters the system, the lower
his or her probability of re-entrance becomes. This is reasonable due to the fact that
the more layers that are taken from the patient, the lower the probability of another
layer being needed is. Our final point describes the function of β. For different types
of patients or physician practices, the expected number of layers required per patient
changes. For example, in an area with a high prevalence of skin cancer, patients in
general may require more layers to completely excise the tumor. Alternatively, if a
physician is prone to taking much deeper layers than another physician in his area,
his patients may in general require less layers. Since a decrease in β corresponds to
an increase in pr(n, β), a patient’s probability at a given value of n is higher for a
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smaller β. This means that while β decreases, the probability of a patient re-entering
the system increases. Some examples of pr(n, β) are displayed in Figure 3.1.



































Figure 3.1.: Re-entrant Probability for Various β
Using this set of requirements and assumptions, a simulation model was developed
and analyzed for various values of k and β. The service times utilized in the simulation
are estimates derived from a wide variety of basic MMS literature, such as patient
pamphlets, physician websites, and MMS overviews [37–39]. However, these resources
did not provide distributions, but rather a range of maxima and minima. Since the
gamma distribution is used to model healthcare service times [12, 35] we decided to
approximate a gamma distribution using a triangular distribution. We found various
values for service times from these sources and used them to approximate a triangular
distribution. A triangular distribution has three parameters, a, b, and c, with a and b
as the minimum and maximum values respectively and c as the mode. The parameters
we used for the distributions are as follows. For the physician, we used fphys(a, b, c) =
fphys(10, 30, 15) and for pathology, we used fpath(a, b, c) = fpath(15, 45, 40). We were
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then able to calculate the variation of the proposed triangular distributions using the
mode (c) as an estimate of the mean and the variance of the triangular distribution for
the variance of the gamma distribution. This enabled us to calculate the parameters
of each gamma distribution, α and β in Γ(α, β). They took the form of Γphys =
(12.45, 0.83) and Γpath = (37.20, 0.93). These distributions are seen in Figures 3.2
and 3.3.













Figure 3.2.: Γphys = (12.45, 0.83)














Figure 3.3.: Γpath = (37.20, 0.93)
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3.2 Experimental Conditions
To conduct the analysis, an objective function was established. In our objective
function, our goal was to pair revenue with overtime costs while maintaining a per-
spective on the amount of waiting time each patient experiences. To accomplish this,
we applied a wait time disutility, a cost incurred by the clinic for each hour a patient
is made to wait. This function is of the form
F (S) = (r ∗ Vphys)− (cw ∗Wtotal)− (co ∗Ot) (3.2)
where r is the reward for one layer of MMS or wound repair, cw is the disutility
of patient wait time, and co is the cost of clinic overtime. Vphys is defined as the
total physician visits, Wtotal is the total patient wait time, and Ot is the amount of
overtime. Here we consider only the physician visits because these are the sessions
that generate revenue, as opposed to the pathology analysis. The following conditions
were set for the analysis.
• r = $300, cw = $100/hr, and co = $800/hr
• β = [1.0, 0.9, 0.8, .., 0.1]
• Each simulation run corresponds to one day of clinic operation
• Clinic simulation for 100 days
• Patients scheduled to earliest available slots
• Slots are 30 minutes in length
• One patient per slot




By using the determined levels of r, cw, co, simulation runs were conducted using
the range of values of both k and β. β values were varied from 0.1 to 1.0 in increments
of 0.1. For each set value of β, we begin by simulating only a single patient being
scheduled, k = 1. When then increase the value of k for each set of runs until our
objective function value is negative. Upon analysis, it was found that the objective
functions were unimodal when varying k across a constant β for the values of r, cw
and co we selected. This allowed us to determine optimal levels of patient scheduling
for each beta. These results are presented in Table 3.1 and Figure 3.4.




























Figure 3.4.: Objective Functions for Various β
This optimal level, kopt, was found to be a function of β with
kopt = 3.163 ln(β) + 9.806. (3.3)
We should note some of the characteristics of this result. As our β coefficient
increases, a patient’s expected number of physician visits decreases. This character-
istic is validated in these results, as demonstrated in Table 3.1, both the number of
patients treated and the maximum value of the objective function increase. When
20
Table 3.1: Optimal Objective Function Values











considering this in the framework of our probability function, this is a reasonable
result. Having patients repeat less in our system means less penalty for the disutility
of waiting in the clinic, not only enabling more patients to be scheduled, but also
adding additional reward without the waiting cost. What we have determined here is
that with a brief study of a clinic’s operations to determine its parameters including
cost-reward structure, service times, and average patient repetitions, we can use this
model to determine an optimal number of patients to schedule per day.
3.4 Numerical Analysis of Simulation Results
Our next area of analysis was to examine the behavior of simulated clinic under
various combinations of our costs, cw and cO and our system parameters β and k. We
can begin by exploring β and its implications. We already know that a decrease in
β corresponds to an increase in re-entrant probability for a set value of n. However,
21
what we do not know is what is the expected number of treatments for a specific
value of β
In order to calculate the expected number of treatments, we needed to evaluate
our probability of re-entrance. When looking at the nature of our system, we can view
re-entering the system as a “failure” and exiting the system as a “success”. Thinking
like this, we can draw a comparison between our probability distribution and the
geometric distribution. The geometric distribution as we are referencing it is defined
as the probability distribution of the number of Bernoulli trials, X, needed to get
one success. In our instance however, we do not have Bernoulli trials with a constant
probability of success. Our probability changes with each increment of n. Because of
this, we cannot just raise our probability of failure to the (k − 1). What we need to
do is compute a product from 1 to k − 1 of our failure probabilities while evaluating
our probability of success at k. We begin by looking at these probabilities at a few
early points, defining p as the probability of re-entering the queue and q = (1 − p)
as the probability of exiting the queue. These basic calculations are demonstrated in
Table 3.2. Knowing that expected values take the form of E[X] = xp(x) we know
Table 3.2: Probability Calculations
n P (N = n)
2 q(2) ∗ p(1)
3 q(3) ∗ p(2) ∗ p(1)
4 q(4) ∗ p(3) ∗ p(2) ∗ p(1)
...
...
n q(n) ∗ p(n− 1) ∗ · · · ∗ p(1)












Now, we know that our probability of failure is our probability of re-entering the
queue, so p = pr and q = (1−pr). Substituting these into our expected value equation








The relationship between β and E[n] is demonstrated in Table 3.3. For convenience,
Figure 3.1 has been reproduced in Figure 3.5.















































Figure 3.5.: Re-entrant Probability for Various β
For our analyses, we use the following conditions.
• r = $300, cw = $100/hr, and co = $800/hr
• β = [1.0, 0.9, 0.8, .., 0.1]
• Each simulation run corresponds to one day of clinic operation
• Clinic simulation for 100 days
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We begin by exploring R, which we will define as the total revenue. If we label each
patient k, each patient receives nk services. We have a total of K patients. As such,





This equation makes it clear that R is a function of our reward, r, and the number





wkcw = cwWtotal (3.7)
Here wk corresponds to the amount of waiting time for patient i and Cw is the total
waiting cost. We will define overtime more simply and only in relation to the clinic.
CO = coOt (3.8)
Our first goal was to examine the effect on the current practice model if we assumed
a constant R. As mentioned, R is a function of the number of patients serviced and
how many services each one has. As such, to fix R, we can instead fix E[N ], where
N is the sum of all services. Therefore, instead of fixing R, we fix the total number
of services provided. This is done for each β. The difficulty in this arises in that we
are dealing with patients, so we must operate with only integer values of k. To do
this, we assembled a set of k values, one for each β that leads to the closes levels of
E[N] possible. These are outlined in Table 3.4. These values lead to E[N ] = 23.20,
σ2E[N ] = 0.87 and a spread of 2.20. The simulation results of this analysis can be
viewed in Table 3.5 and Figure 3.6.
As can been seen in Figure 3.6, with a constant E[N ], as β increases, we see a
steadily decreasing objective function value, F (S). This can be attributed to the
increasing (or more negative, since the weights for Cw and CO are negative) total
costs. The small variations in the changes can be attributed to the inconsistencies of
our R value. What this is telling us is that as our re-entrant probability increases,
even if we attempt to maintain a constant E[N ], our wait time and overtime costs
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Table 3.4: Constant R Values











increase. So under these set experimental conditions, we have observed that for a
constant R, as β decreases, Cw and CO increase, and therefore F (S) decreases.













Figure 3.6.: Simulation Results with Constant R
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Table 3.5: Simulation Results for Constant R
β k F (S) R Cw CO
1 11 4196.82 7317 -2240.9 -879.2
0.9 10 4245.31 6729 -1974.5 -508.8
0.8 10 3964.69 6930 -2199.2 -766.4
0.7 10 3630.73 7161 -2485.0 -1045.6
0.6 9 3429.19 6744 -2397.9 -916.8
0.5 9 2948.06 7086 -2776.7 -1361.6
0.4 8 2869.30 6696 -2638.4 -1188.0
0.3 8 1988.02 7350 -3274.4 -2087.2
0.2 7 1372.35 7341 -3389.1 -2579.2
0.1 5 1318.17 6777 -2814.8 -2644.0
A second perspective was obtained by maintaining a constant k for each β value.
For this, we selected an average value of k = 8. The results for this are displayed in
Table 3.6 and Figure 3.7.
As can be seen in Table 3.6 and Figure 3.7, again as β decreases, we see an
overall decrease in F (S). This is due to the fact that while our R value does increase
exponentially, both Cw and CO also increase exponentially. As such, under these
experimental conditions we have observed that for a constant k, as β decreases, R,
Cw and CO increase, and therefore F (S) decreases . These two combine into a slightly
counter-intuitive view of our system. One would expect that having more difficult
procedures leads to more treatments which would increase the overall profit. However,
what is being observed is that with the inclusion of waiting time, having patients that
spend less time in the system individually makes more economic sense. This clearly
point to the importance of the relationship between our revenue, R, and our waiting
and overtime costs, Cw and CO. These results must be treated carefully. If such a view
were to be adopted by clinics on a large scale, patients who are expected to require
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Table 3.6: Simulation Results for Constant k
β k F (S) R Cw CO
1 8 3911.972 5184 -1242.8 -29.6
0.9 8 3901.874 5298 -1336.7 -59.2
0.8 8 3850.082 5415 -1457.9 -107.2
0.7 8 3776.693 5604 -1640.7 -186.4
0.6 8 3635.437 5880 -1891.6 -352.8
0.5 8 3366.923 6228 -2192.4 -668.8
0.4 8 2869.305 6696 -2638.4 -1188.0
0.3 8 1988.021 7350 -3274.4 -2087.2
0.2 8 439.576 8298 -4344.9 -3513.6
0.1 8 -3549.223 10959 -6850.9 -7657.6












Figure 3.7.: Simulation Results with Constant k
27
more complex procedures could be shunned by clinics attempting to maximize the
customer experience. Further work is planned to evaluate the impact of a changing
ratio of these values.
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4. PROPOSED QUALITATIVE SCHEDULING
CONSTRAINTS
The next area of study was to attempt to create heuristics based on Webb and Rivera’s
WAR Score [28]. These heuristics would attempt to analyze patient characteristics
and score patients based on their level of risk for extensive subclinical spread. As
mentioned previously, it is extremely difficult to determine the amount of subclinical
spread simply from a carcinoma’s physical presentation. In response to this, we have
identified patient characteristics that place patients at increased risk for subclinical
spread. To begin these types of analyses, we began by developing methods for gener-
ating random patients. This was accomplished using data sets in Batra’s two papers,
Predictors and Risk Scale [30, 31]
4.1 Method of Patient Generation and Scoring
The two data sets presented in the previously mentioned papers were combined in
order to obtain the percent of MMS patients who had each of the characteristics iden-
tified as relevant by Batra [30]. The probabilities for each of the patient characteristic
groups are in Tables 4.1, 4.2, and 4.3.
To use these tables, we sum the values, assigning each characteristic a segment of
[0,1]. We then generate a random uniform [0,1] number and assign to that patient
the characteristic whose area the generated number falls into. A new random number
is generated for each test. Our next characteristic to consider is the size of the
carcinoma. We found that carcinomas follow a truncated normal distribution with
the parameters µ = 11.9mm and σ = 8.9mm2 [28]. As such, the size is generated
according to this distribution. Scoring the patients is then completed as described in
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SCC in situ 0.041
Recurrent SCC 0.011
Other 0.017
















the two papers WAR Score and Risk Scale [28,31]. These rules for Batra’s Risk Scale
are displayed in Table 4.4 and WAR Score rules are displayed in Table 4.5.
For the Risk Scale Predictor Scores [30,31], the highest possible score is selected.
For example, if a patients has a 10 − 20mm (score of 5) basosquamous BCC on the
nose (score), the patient will receive a score of 19. In contrast, the scores provided
by the WAR score [28] are additive. Here, if a patient has a 2.5cm(+2) recurrent
(+1) tumor on the ear (+1) of an aggressive subtype (+1), the patient would receive
a score of 5.
For the Risk Scale analyses we the divide patients into “Risk Groups” based
on these values. These risk scores are then used to do two additional calculations,
assigning values for high/low risk lesions for extensive subclinical spread and the
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Table 4.4: Batra Risk Scale Predictor Scores [31]
Predictive Characteristic(s) Point
Basosquamous BCC on nose 19
Morpheaform BCC on nose 19
Morpheaform BCC on cheek 18
Recurrent BCC on nose 17
Lesion on ear helix 16
Size > 20mm 14
Recurrent BCC in men 13
Neck tumors in men 12
Eyelid 9
Nodular BCC on nose 9
Temple 8
Size 10− 20mm 5
Table 4.5: Webb and Rivera (WAR) Scoring [28]
Size (cm) Point Occurence Point Location Point Subtype Point
0− 0.9 +0 Primary +0 Other +0 Non-aggressive +0
1− 1.9 +1 Recurrence +1 Nose, ear, +1 Aggressive +1
2− 2.9 +2 eyelid, lip
≥ 3.0 +3
expected number of Mohs layers required. These are done in the same manner as the
generation of patient characteristics, with high/low risk determined by data pulled
directly from Risk Scale [31] and the number of Mohs layers expected derived from
data in both Risk Scale [31] and Predictors [30]. For high risk/low risk, if a patient
meets the probability for extensive subclinical spread, they are deemed a high risk
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patient, otherwise they are considered low risk. Low risk patients are defined as
expecting only 1-2 Mohs layers to fully excise the lesion. High risk patients are
expected to require 3-6 layers. Based on the point values, we assign patients to the
Risk Groups outlined in Table 4.6 and give them probabilities of being at high risk
for extensive subclinical spread.
Table 4.6: Risk Group Extensive Subclinical Spread Probabilities [30] [31]







From the data in Risk Scale [31] and Predictors [30] we were able to derive the
probabilities, p(n), on how many layers patients in both the high and low risk groups
could expect to have. The results are featured in Table 4.7.
Table 4.7: Risk Level Expected Layers [30] [31]
Low Risk High Risk
n p(n) n p(n)
1 0.35 3 0.65




4.2 Set of Proposed Scheduling Constraints
Currently, twelve sets of constraints are being used in the simulation. The primary
sets are based on the WAR Score [28] and two alternate versions of Batra’s Risk
Scale [31]. Each one of these then has three additional variations. We chose the
following variations for each set: Alternating Difficulty, Longest Expected Processing
Time First (LEPTF) and Shortest Expected Processing Time First (SEPTF). Here
when we speak of expected processing time, what we are using as an indicator of this
is either the WAR Score [28] or the Risk Group. Longer expected processing time
means the patient is in a group more prone to needing additional layers. As such,
the higher the WAR Score or the Risk Group, the longer the expected processing
time. The opposite is true for shortest expected processing time. The logic behind
alternating the difficulty comes in attempting to isolate the patients we expect to
require more re-entrances into the system. This way they are spread out in the
system and should not cause as significant of a bottleneck. LEPTF was chosen to
place all difficult patients earliest with the objective of reducing the risk of overtime
in the system. SEPTF was chosen because in many scheduling applications, this is
often used as a method to reduce overall system time. The basis of the WAR Score
is to rank procedures by how difficult they may be [28]. The only problem with this
definition is that “difficulty” is a subjective term. This is mostly determined by how
long the patient will have to remain at the clinic, but other factors do interact. It
functions by reviewing the characteristics of a patient and assigning point values to
certain characteristics and summing the patients score. All sets of rules are for a
given number of patients per day (e.g. 8 in this study). In his paper, Webb proposes
a basic application of the WAR score which utilizes the following rules for a total of
8 patients.
1. A maximum of two patients per day with a WAR score of 3+
2. A maximum of two patients per day with a WAR score of 2
3. All remaining patients must have a WAR score of 0 or 1.
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In our execution, we will be scheduling a total of 8 patients. Table 4.8 outlines the
possible patient sets. Sets are grouped horizontally. For example, if we have a call-in
Table 4.8: Possible WAR Score Combinations from Webb [28]
WAR Scores










system and three patients with score of 2 and three patients with scores of 3 or larger
call in, one of each of these patients will be scheduled the next day. This will lead
to a maximum of two 3+ patients, two 2 patients, and a between four and eight
0-1 patients. This appears to be a reasonable on-the-fly application, but we have
proposed two alternate forms of this scoring system due to the fact that the patients
are still scheduled on a FCFS basis, thus leaving the difficulty randomly distributed
throughout the day. To counter this, we proposed scheduling patients using the Webb
heuristic (WAR Score [28]) but following a few extra step relating to the ordering of
the schedule. These versions are seen in Table 4.9.
The important thing to note here is that patients are still taken on at a FCFS
basis and will only be rejected if they violate the stated rules. For example with
initial heuristic from Webb, if there are already two 3+ patients scheduled and a
third comes up, the patient will be rejected. However, this is not saying that we will
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Table 4.9: WAR Score Alternate Rules [28]
WAR Score Variant 1: Alternating
Maximum of 4 patients per day with WAR score 2+
Fill remaining patient slots with WAR score 0 or 1
Alternate patients of 2+ and 0,1 starting with 2+
WAR Score Variant 2: LEPTF
Maximum of 4 patients per day with WAR score 2+
Fill remaining patient slots with WAR score 0 or 1
Longest Expected Processing Time First
WAR Score Variant 3: SEPTF
Maximum of 4 patients per day with WAR score 2+
Fill remaining patient slots with WAR score 0 or 1
Shortest Expected Processing Time First
always have four 2+ patients and four 0,1 patients. This applies to all of the versions
here.
The second and third sets of heuristics are derivations from Batra’s Risk Scale [31].
As stated previously, in this paper she presents a point system to help determine the
chances that a patient experiences extensive subclinical spread, defined as requiring
three or more Mohs layers to fully excise. The risk groups are segmented into groups
in two different manners in the two sets of heuristics based on the Risk Scale. These
policies are outlined in Tables 4.10 - 4.12.
The reasoning behind regrouping the risk groups lies in the fact that we want
these heuristics to be able to be used on-the-fly by physicians. Having different as-
signing rules for each of the five risk groups seemed overly complicated for such an
approach. However, the actual regrouping decisions were more difficult, hence the
result of two separate policies. The rules for each of these polices are very similar to
those of the WAR score and its alternative versions. The primary difference between
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Table 4.10: Policy Risk Group Organization






Table 4.11: Risk Scale Policy A Versions
Risk Score Policy A Policy A Variant 1: Alternating
Maximum of 4 patients of rank 2 Maximum of 4 patients of rank 2
All remaining patients rank 1 All remaining patients rank
Alternate patients of ranks 1 and 2
Policy A Variant 2: LEPTF Policy A Variant 3: SEPTF
Maximum of 4 patients of rank 2 Maximum of 4 patients of rank 2
All remaining patients rank 1 All remaining patients rank 1
Longest expected processing time first Shortest expected processing time first
ranking the patients by their WAR score and their Risk Score is that the WAR score
emphasizes the amount of time that the patient will take to treat, from first cut to
final healing decision, while the Risk Score is completely dependent on the number
of Mohs layers that are expected to be needed to fully excise the lesion. Again, the
initial versions of the Risk Score policies focus only on the numbers of each specific
rank that we are allowed to schedule each day. The alternate versions of it focus
on ordering the patients in specific ways, attempting to improve on the constrained
FCFS method that was originally used. The alternating of difficult/long procedures
with easier/shorter procedure is designed to provide the physician with extra time
to complete the more difficult case while still completing another case. It is possible
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Table 4.12: Risk Scale Policy B Versions
Risk Score Policy B Policy B Variant 1: Alternating
Maximum of 2 rank 3 patients Maximum of 2 rank 3 patients
Maximum of 2 rank 2 patients Maximum of 2 rank 2 patients
All remaining patients rank 1 All remaining patients rank 1
Alternate rank 2+ and rank 1
Policy B Variant 2: LEPTF Policy B Variant 3: SEPTF
Maximum of 2 rank 3 patients Maximum of 2 rank 3 patients
Maximum of 2 rank 2 patients Maximum of 2 rank 2 patients
All remaining patients rank 1 All remaining patients rank 1
Longest expected processing time first2 Shortest expected processing time first
though that the shorter/easier patients will end up being bottlenecked by the more
difficult cases surrounding them. In an attempt to alleviate this, the second variation
was proposed. By scheduling all difficult cases early, they may delay and interact
with each other, but the effect may be less severe than the effect these delays would
have on the shorter cases. The third variation is to schedule the easiest cases earlier
in the morning in an attempt to drive down over all waiting times by minimizing the
initial bottleneck.
4.3 Simulation and Numerical Analyses of Proposed Constraints
Analysis of the effectiveness of the heuristics was accomplished through a simula-
tion model. The experimental conditions are as follows.
• r = $300, cw = $100/hr, and co = $800/hr
• Each simulation run corresponds to one day of clinic operation
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Table 4.13: Time in System
Heuristic Min Avg Max
FCFS 156.29 400.737 604.269
RiskA 156.181 399.489 602.219
RiskA: Alt 158.426 401.954 602.342
RiskA: LEPTF 156.136 392.196 585.450
RiskA: SEPTF 145.515 382.105 585.729
RiskB 156.415 394.636 592.919
RiskB: Alt 157.983 396.202 592.782
RiskB: LEPTF 158.346 393.085 585.393
RiskB: SEPTF 145.211 380.663 585.702
Webb 155.973 397.822 600.318
Webb: Alt 156.451 398.672 600.280
Webb: LEPTF 159.094 397.759 595.018
Webb: SEPTF 146.449 388.629 594.943
• 8 patients scheduled per day
• Patients scheduled to first 8 slots
• Slots are 30 minutes in length
• Clinic simulation for 1000 days
Groups of random patients were generated, sorted (if applicable), and fed into the
simulation model. Several key performance measures were analyzed for each heuristic,
including average wait times, average time in system, and resource utilization. These
measures can be viewed in Tables 4.13, 4.14, 4.14 and 4.16. All results are in minutes.
As can be seen from the results, the impact of the proposed heuristics is mini-
mal at best. In relation to the time each patient spends in the system, the proposed
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Table 4.14: Time in Phys Queue
Heuristic Min Avg Max
FCFS 0 13.446 68.677
RiskA 0 13.473 68.677
RiskA: Alt 0 13.473 68.677
RiskA: LEPTF 0 13.734 68.677
RiskA: SEPTF 0 13.734 68.677
RiskB 0 13.624 68.677
RiskB: Alt 0 13.624 68.677
RiskB: LEPTF 0 13.734 68.677
RiskB: SEPTF 0 13.734 68.677
Webb 0 13.505 68.677
Webb: Alt 0 13.505 68.677
Webb: LEPTF 0 13.575 68.677
Webb: SEPTF 0 13.575 68.677
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Table 4.15: Time in Path Queue
Heuristic Min Avg Max
FCFS 0 120.857 216.662
RiskA 0 120.851 216.649
RiskA: Alt 0 122.008 216.844
RiskA: LEPTF 0 122.248 217.858
RiskA: SEPTF 0 117.515 212.99
RiskB 0 121.211 216.669
RiskB: Alt 0 121.969 216.559
RiskB: LEPTF 0 122.644 218.568
RiskB: SEPTF 0 116.839 212.744
Webb 0 120.716 216.754
Webb: Alt 0 121.102 216.405
Webb: LEPTF 0 122.196 218.458
Webb: SEPTF 0 117.964 213.081
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RiskA: Alt 0.426 0.957
RiskA: LEPTF 0.430 0.956
RiskA: SEPTF 0.429 0.954
RiskB 0.428 0.956
RiskB: Alt 0.429 0.956
RiskB: LEPTF 0.430 0.956
RiskB: SEPTF 0.429 0.954
Webb 0.426 0.956
Webb: Alt 0.426 0.956
Webb: LEPTF 0.428 0.956
Webb: SEPTF 0.427 0.955
scheduling sets due generally perform better, but only marginally so. This is a general
trend throughout all of the presented results. Overall, the SEPTF methods do out-
perform the others in overall time in system, but this does not necessarily translate
to both wait time in the pathology and physician queues. We believe these results
may be due to a weakness in our patient generation data.
One of the potential difficulties associated with using the Batra data is that both
sets of data are collected from the same hospital, namely the Beth Israel Deaconess
Medical Center in Boston, MA [30] [31]. One of the leading causes of skin cancer is
overexposure to sunlight [2], which varies from location to location. For example, one
would expect to see higher incidence rates of overexposure in areas known for being
sunny, such as Florida, Texas, or Australia, and less in areas that are not sunny, such
as Maine, Massachusetts, or Canada. This difference may lead to the data being
41
generated having a specific skew associated with the area in which it was collected.
To further analyze the Batra data, frequency data was calculated on three specific
characteristics: the expected number of Mohs layers, the calculated WAR score, and
the Batra Risk Score. These are represented in Figures 4.1, 4.2, and 4.3.















Figure 4.1.: Expected Layer Frequencies














Figure 4.2.: Risk Score Frequencies














Figure 4.3.: WAR Score Frequencies
The important characteristic to note here is the major skew to lower scores and less
layers. When reviewing patients who experience extensive subclinical spread, defined
previously as requiring three or more Mohs layers, this characteristic applies to only
21.96% of all patients generated. Since the heuristics proposed based on Batra’s Risk
Score [31] are focused around controlling the number of patients with a high risk of
extensive subclinical spread the physician would see in a day, it is reasonable that
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Table 4.17: Number of Changes Made to Schedule
Model Min Avg Max
Webb 13,232 13,673 14074
Risk A 879 992 1093
Risk B 21934 22,397 22975
the proposed heuristics would have little to no effect on the average amount of time
spent at the clinic by patients. With so few at risk patients existing in the patient
pool, few patients will not be scheduled due to violating the constraints on at risk
patients. A similar statement can be made about the WAR Score data [28]. The rules
for scheduling patients according to the WAR score heuristics control patients of rank
two and three or higher. A maximum of two patients with WAR scores of both 2 and
3+ can be scheduled a day. With a daily schedule consisting of eight patients, that
means a maximum of 25% of the scheduling capacity can be assigned to each of these
categories, with 50% remaining for patients of scores 0 and 1. With patients of rank
2 populating only 30% of the patient pool and patients with scores 3+ consisting of
a mere 14% of the population, it becomes readily apparent how the scheduling rules
will have little effect on the actual patients being seen by the physician.
To further explore this area, a comparison was done between the initial FCFS
patient lists and the unsorted (first version) of each of the heuristic sets to see how
man patients were being dropped or moved in the lists. To do this, 100 sets of the total
patient lists were generated and compared. The total patients in each set is 80,000.
The results can be seen in Table 4.17. The results demonstrate that few patients
out of the pool are actually being moved or declined based on the added rules with
only 17.09%, 1.24%, and 28.00% being changed on average in each model, respectively.
This has been identified as a weakness in the data, but various solutions to the problem
exist. Proposed solutions to this difficulty include either obtaining similar data from
literature from other parts of the country and world or artificially generating data with
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a wider variety of frequency distributions. With the minimal literature that exists
in the area, obtaining additional data sets without conducting additional surveys
around the globe seems to have a minimal chance of occurrence. However, it should
be very simple to produce alternative data sets and see their effect on the model. This
can be accomplished by directly altering the WAR score, Risk Score, and Expected
Layers, or by simply selecting characteristics that push these scores up and increasing
their probability of occurring. Finally, the proposed heuristics can simply be made
much stricter in order to account for the data. Additionally, the constraints could be
reformulated for various types of data sets to increase their generalizability.
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5. PROPOSED SEQUENTIAL SCHEDULING POLICY
FOR MMS CLINICS
Our proposed scheduling policy consists of a call-in system in which patients are
generated and then scheduled. At the time of each patient’s scheduling, an objective
function is analyzed in order to choose the best slot for the patient to be scheduled
for based on the current schedule and the patient type.
5.1 Parameters and Definitions of Scheduling Policy
Our system in this approach has the following characteristics.
• Patients are scheduled sequentially and cannot affect a preceding patient’s ap-
pointment time.
• We use a myopic policy, only considering the upcoming patient and not any
future call-in schedule.
• A schedule corresponds to a single day’s operation
• Our algorithm attempts to maximize a combination of the revenue, wait time
disutility, and overtime costs.
• We assume homogeneous patient behavior in both no-show, pns, and re-entrant,
pr, probabilities.
• We have a 2 server, 2 stage system consisting of physician and pathology, but
we reduce to 1-1 for tractability.
• We assume patient punctuality.
• We do not fix the number of patients that can be scheduled each day.
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Figure 5.1.: The system.
In most clinic modeling approaches, a scheduling matrix, S of size I×J is used, where
Sij represents the number of patients of type j scheduled in slot i. However, since
we assume completely homogeneous patients, J = 1, so we instead have a scheduling
vector Si. We assume a standard workday of 8 hours with 30 minute slots, leading to
I = 16 slots per day. We also define λ as the expected number of patients that can
be serviced during each slot’s time period, assuming exponential service time. This
characteristic can also be utilized to control the length of the slots, changing it in
relation to the length of the slot. For example, if we originally have 30 minute slots
and expect to be able to serve 2 patients during each slot (approximate service time
of 15 minutes), changing the length of our slot to 15 minutes would correspond to a
change in λ from 2 to 1. λ is also used to account for changes in service time. Our
system is demonstrated in Figure 5.1.
The system variables are defined as follows.
• I: number of time slots
• pns: the probability of a patient not showing up for a scheduled slot
• pr: the probability that a new treatment is needed after the treatment of a
patient in slot i, the new treatment will assigned to slot i+ 1.
• D: the length of each time slot
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• λ: the expected number of treatments completed provided there are infinitely
many treatments assign to this slot and assuming exponentially distributed
service time for each treatment (this means the expected service time is D
λ
)
It should be noted here that with the variables defined as above, all patients have
identical no-show and re-entrant probabilities and that each time slot i is assumed to
be equal in length.
• Si: our schedule vector, Si is the number of patients assigned to slot i during
the call-in period
• Sn: our schedule after the nth optimal assignment
• Xi: number of scheduled patients who show up for slot i. Xi depends on the
schedule S and is a random variable
• Li: number of patients treated in slot i, provided the queue is long enough
– Li is a Poisson random variable because we assume exponential service
time
Due to the fact that a treatment completed in slot i has a probability of generating
an additional treatment in slot i + 1 (our re-entrants), we define Zi in the following
manner.
• Zi: number of patients who re-enter the system following treatment in slot i−1
• Yi: number of patients who overflow from slot i
– Yi = max{Yi−1 +Xi + Zi − Li, 0}
• Ti: number of patients treated in slot i
– Ti = min{Yi−1 +Xi + Zi, Li}
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5.2 Execution of Sequential Scheduling Algorithm
We will indicate a day’s schedule after n patient call-ins as Sn ∈ RI , so Sni
represents the number of patients scheduled in slot i after n call-ins. Additionally,
we will define an assignment vector ∆i of length I which consists of a one at the ith
position and zeros at all others. We will also set U as the set of all slots i. The model
then uses a cost-reward structure to create a value function that is dependent on our
schedule, S. We set r as the reward for each treatment of a patient and ci as the
cost of a patient overflowing from slot i. It should be noted that ci = cw for all slots
except that ci < cI due to the cost of overflow from the last slot being more expensive
due to overtime costs. In this instance, cI = cO. As such, we can structure our value
function with the following characteristics: reward for each patient treated, costs for
each patient overflow, net reward for each expected treatment during the overtime







ciYi + (r− cI)ZI+1 + (r− cI)(Yi +Zi+1) pr
1− pr ] (5.1)
5.2.1 Probability Derivations
To compute this function, we need the expectations of Xi, Yi, and Zi. The expec-
tation of Xi is simple enough, since it is a binomial random variable following (Si, pa).
To do this calculation, we can set Qik, the probability of k patients arriving in slot i.
We will set pa = 1− pns.
















If we attempt to define Zi in the following manner, we quickly realize that this is not
possible without conditioning the probability on Ti. However, we can still state that
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Zi+1 is a binomial random variable with parameters Ti and pr. As such, let us define
bn as a random variable following Binomial(n, pr) and set Zi+1 = bTi . With this in
mind we can now look at the joint distribution of (Yi, Zi+1) which can be calculated
recursively.
P (Yi = y, Zi+1 = z) =
∑
t








P (Yi = y, Ti = t)P (bt = z)
(5.4)
Knowing the parameters and distribution of P (bt = z), we can now separate P (Yi =
y, Ti = t) and solve for it.




P (Yi = y, Ti = t|Yi−1 = yi−1, Zi = zi, Xi = xi, Li = li)·




P (Yi = y, Ti = t|Yi−1 = yi−1, Zi = zi, Xi = xi, Li = li)·
P (Yi−1 = yi−1Zi = zi)P (Xi = xi)P (Li = li)
(5.5)
Using the definitions of Y and T we can then write
P (Yi = y, Ti = t) =

1 if
y = max{yi−1 + xi + zi − li, 0} and
t = min{yi−1 + x+ zi, li}
0 otherwise
(5.6)
Using this equation, we can state the following.
P (Y0 = y, Z1 = z) =
1 if y=0 and z=00 otherwise (5.7)
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As such, by utilizing (5.4), (5.5), (5.6) and (5.7), we can compute P (Y i = y, Zi+1 = z)
recursively. Thus, to find the expectation of both Yi and Zi, we need to use these
















P (Yi = y, Ti = t)P (bt = z) (5.9)
In this instance, we have the expression for P (Yi = y, Ti = t) and we know that bt









P (Yi = y, Ti = t)P (bt = z) (5.10)







P (Yi = y, Ti = t) (5.11)
5.2.2 The Scheduling Policy
The primary outputs of this model then are a vector of objective function values
for each time a patient is added and an overall schedule for the total number of
patients scheduled. The scheduling algorithm executes in the following manner.
1. Set Si = 0 ∀ i ∈ U
2. Wait for nth call
3. nth call occurs
4. For each i ∈ U
(a) Set Sni = S
n−1 + ∆i
(b) Compute f(Sni )
5. If fni ≥ fn−1
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(a) i∗ = argmaxfni , S
n = Sn−1 + ∆i
∗
(b) Set n = n+ 1, Go to Step 2
(c) Else Stop.
The objective function is unimodal as we add patients, so that point at which
it obtains its maximum value is used to select our schedule. The schedule is then
accepted up to the number of patients at which our optimal objective function value
occurs. It should be noted that while our scheduling policy penalizes based on ex-
pected overflow, our simulation model objective function is based upon total waiting
time. As such, it would be useful to have expressions for the expected total waiting
time for a given schedule to enable a more accurate comparison of the expected results
of the schedule and the simulated results.
5.2.3 Expected Total Waiting Time Derivations
We begin by looking at the expected waiting time for all patients in a specific
slot i. If we state that there are N patients in this slot, then we can state that
Xi + Yi−1 + Zi = N . We can also define µn as the actual service time for the nth
patient in this slot assuming that the slot were of infinite length. Looking at this,
we know that the first patient, n = 1 has no waiting time in this slot as they are the
first to be serviced. Every other patient though must wait for all others before them
to complete service. As such, the nth patient will need to wait for n − 1 services to
be completed before his or her service begins. However, as defined previously, each
slot is of length D, thus making D the maximum amount of waiting time per patient
in each slot. This leads to the following statements: the total waiting time for the
nth patient in slot i is defined as min(D,
∑n−1
k=0 µk, ), and µ0 ≡ 0. We know that
the service time for each patient is independent and identically distributed following
an assumed exponential distribution. As such, the waiting time for the nth patient,
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given that n ≥ 2 is a truncated Gamma( λ
D
, n − 1) random variable. The expected












(n− 2)! dx (5.12)
Using this equation, we can state the expected total waiting time in any slot, which






















This equation though is not generalizable to the waiting in the overtime period. In
the overtime period, we can state the expected number of treatments required by a
patient as 1
1−pr . Following this logic, the expected length of the overtime period is∑
N≥1 P (YI +ZI+1 = N) · N1−pr . We will denote the total waiting time for all patients
in the overtime period as WO(N) given that there are N patients in the system at
the beginning of the overtime period. By definition WO(0) = WO(1) = 0, as there
will be no waiting time in the overtime period if there are not at least two patients





· (N − 1) + (1− pr)E[WO(N − 1)] + pr ·E[WO(N)], N ≥ 1. (5.14)
This equation has multiple parts. This first term indicates the amount of waiting
time for the N−1 patients who are waiting during the first treatment in the overtime
period. After this treatment is completed though, that patient will leave the system
with a probability of (1− pr). The leads us to the second term, the expected waiting
time of the remaining N −1 patients. However, the patient who completes treatment
also has a probability, pr, of re-entering the system. If this were to occur, the expected
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waiting time in the overtime period would remain the same, leading to the third term.
Re-arranging the terms of both sides of (5.14), we have the following.
E[WO(N)] =
D
λ · (1− pr) · (N − 1) + E[WO(N − 1)], N ≥ 1.
=
D
λ · (1− pr) · [0 + 1 + 2 + · · ·+N − 1] + E[WO(0)]
=
D




Thus, the total expected waiting time is given by the following.∑
N≥1
D
λ · (1− pr) ·
N(N − 1)
2
· P (YI + ZI+1 = N) (5.16)
5.2.4 Model Weaknesses
The problems that we see with this model can be described in terms of its levels
of abstraction. The primary area in which the model deviates is the inclusion of
only one service type, the physician. As such, the model lacks the double service
characteristic of the actual clinic, limiting the applicability of its results. Also, the
model assumes a constant re-entrant probability for all patients. This is also not
completely accurate, as the more times a patient has been treated by the physician,
the lower his/her probability of re-entering the queue should be, according to our re-
entrant probability model. Also, the calculations in the scheduling policy are based
around overflow, rather than expected wait time. While we do have expressions
for the expected wait time, the policy still conducts its calculation using overflow.
However, we do still believe that such a model resembles the system enough to justify
a comparison of objective function values obtained by the current practice simulations
and our generated schedules.
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5.3 Simulation Analysis of Generated Schedules
Analysis of the schedules produced through our call-in model was conducted
through the same simulation model used for the current practice analyses. Experi-
mental conditions for the simulation are as follows.
• r = $300, cw = $100/hr, and co = $800/hr
• Each simulation run corresponds to one day of clinic operation
• Slots are 30 minutes in length
• Clinic simulation for 100 days
For tractability of our scheduling policy, it was necessary to set pr as a constant, rather
than pr(n, β). In order to determine the appropriate value of pr, we determined the
expected number of physician visits per patient for our pr(n, β) for the same set of
β values as in our current practice analysis. The expected values in Table 3.3 were
used to determine an equivalent constant re-entrant probability value.
Using the constant probabilities of re-entrance, schedules were then developed for
each level of β. These schedules were then executed in our simulation. In every
execution of the model, we have defined our no-show and re-entrant probabilities as
in our current practice model, specifically, pns = 0.1 and pr = pr(n, β) as defined
in Equation 3.1. For our primary performance measures we selected the objective
function value and the average patient wait time in system. For analysis, we selected
our schedule with λ = 1.5, I = 16 with 30 minute slots, corresponding to a standard
8 hour work day. The results are presented in Table 5.1.
As can be seen in Table 5.1, in situations with larger β (and therefore lower
re-entrant probability), our mathematical model produces favorable results in most
cases, allowing us to schedule similar or larger numbers of patients without increasing
the patient time in system. However, as β approaches its smallest values, our objective
function and time in system values become worse than that of the current practice
simulation. This could easily be a result of the level of abstraction mentioned about
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Table 5.1: Mathematical Model Simulation Results
β k F (S) Time in System
1 9 4426.783 1.973
0.9 9 4476.702 1.970
0.8 8 4197.070 1.930
0.7 8 4153.828 2.793
0.6 8 4131.296 2.372
0.5 8 3883.962 2.682
0.4 7 3574.197 3.035
0.3 7 3030.522 3.772
0.2 6 2641.956 4.613
0.1 5 1497.722 6.313
the model. Since we are forced to utilize a constant probability in our calculations
rather than one that accounts for number of times a patient has already re-entered
the system, it is possible that this reduces are generalizability to small β values. A
comparison of these results to our optimal current practice simulations is presented
in Table 5.2. Of course, our most important comparison is between the F (S) values
of the two methods. Generally, the algorithm produces superior results to the current
practice method. The same can be said for the amount of time each patient can
expect to spend in the system. These do not hold however for the smallest values of
β, the instances were our re-entrant probability is the largest. This could though be
related to the abstraction of the model, especially considering the constant re-entrant
probability used. We have though however demonstrated a baseline that in most
instances, our scheduling algorithm can produce superior results.
Next, we wished to examine some of the relationships between the various cost and
reward weights and the function of our scheduling algorithm. We began this analysis
using two unlikely relationships, cO = r and cO < r. In our test of cO = r, we found
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Table 5.2: Comparison of Current Practice and Mathematical Model Results
Current Practice Scheduling Policy
β k F (S) Time k F (S) Time
1 10 4334.14 2.459 9 4426.783 1.973
0.9 10 4245.31 2.587 9 4476.702 1.970
0.8 9 3991.83 2.718 8 4197.070 1.930
0.7 8 3776.69 2.693 8 4153.828 2.793
0.6 8 3635.44 3.044 8 4131.296 2.372
0.5 8 3366.92 3.490 8 3883.962 2.682
0.4 7 3150.67 3.754 7 3574.197 3.035
0.3 6 2954.59 4.191 7 3030.522 3.772
0.2 4 2740.57 3.991 6 2641.956 4.613
0.1 3 2554.07 4.794 5 1497.722 6.313
when these two measures are equivalent, the system reaches a sort of equilibrium.
After scheduling the k patients in the optimal manner, the system will schedule an
infinite number of patients in the final slot, assuming since the reward is the same
as the cost, a net value of 0 is added each time. This represents a weakness in the
model. It fails to incorporate the wait time of patients scheduled in the overtime slot.
For cO < r, the results are slightly different. In this case, since cO < r, our objective
function is no longer unimodal with respect to k in our scheduling algorithm. Instead,
it is unbounded and will eventually increase linearly with each patient added. The
linear amount at which it increases has been found to be independent of cW and β
(or the equivalent constant pr) while being dependent cO only. The pr only changes
the amount of patients needed to reach the linear increase. However, we have been
unable to determine the relationship between the linear increase and cO.
In the future, our objective is to continue this strain of analysis into the entire
parameter space. We are currently working on the derivation of the expected profit
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for a given schedule, and therefore the expected revenue, waiting time, and overtime.
These derivations should enable us to further experiment with and analyze the be-
havior of the scheduling algorithm to be more able to accurately control its function,
thus enabling it to perform even better against the current practice model.
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6. CONCLUSIONS AND FUTURE WORK
6.1 Conclusions
We have demonstrated three tools in this paper: a method of modeling and sim-
ulating current MMS clinic practice in order to identify optimal number of patients
to schedule, a set of proposed heuristics to be used to increase the patient experience
and an algorithmic scheduling policy. Our current practice model consisted of a sim-
ulation of an MMS clinic. By estimating service times for the two aspects of MMS,
physician visits and pathology, and developing a probability distribution for patient
re-entrant probability with a controlling shape factor β, we were able to produce a
working simulation of the MMS clinic. We conducted analysis through an objective
function that accounted for revenue based on the number of procedures completed,
the disutility of patient wait time, and overtime operating costs. Our objective func-
tion was unimodal for all values of β analyzed, allowing us to identify an optimal
number of patients to schedule for each β value. Such a tool could be used today by
examining the types of patients seen by a physician at an MMS clinic and identifying
an average number of physician services that the patients require. Then by limiting
the maximum number of patients seen to this optimal value, the clinic should be able
to improve the overall patient experience while also improving overall profits. How-
ever, the model did have unexpected impacts, for example indicating that under the
conditions of our objective function, a clinic should attempt to schedule large num-
bers of simple procedures rather than a smaller number of more complex procedures.
Such findings, if put into practice could limit treatment availability to specific patient
groups, so such results must be treated carefully.
Our second tool developed was a set of scheduling constraints designed for on-the-
fly use in an MMS clinic. A series of twelve heuristics were developed and compared
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to a FCFS scheduling policy. Using a simulation model similar to the current practice
model but based on patient characteristics rather than a re-entrant probability, we
were able to conduct an analysis of the heuristics. The proposed heuristics proved
to have little effect on the patient experience, with wait times and utilization levels
remaining nearly constant, even in comparison with the FCFS method. However,
after further analysis it was revealed that this was an effect of the data used in
generating random patients. The data obtained from literature lead to a patient
distribution that was skewed towards less expected layers, leading to our algorithms
having a minimal effect on the schedules themselves. This leads us to the conclusion
that while these heuristics may have some level of applicability depending on the
types of patients being seen at a clinic, they suffer from a lack of generalizability.
If further data sets can be obtained, additional analysis of these heuristics could be
conducted to prove their viability. Additionally, reformulating these constraints for
specific data sets may be possible.
Third, we have demonstrated a myopic sequential scheduling policy for MMS
clinics that maximizes a profit function based on revenue, wait time disutility, and
overtime costs. Our objective in the development of this model was to demonstrate
superior results to those of our current practice model in a parameter space including
β, number of patients, and our cost and reward weights. While the scheduling policy
was used to compare against the current practice model, there were several differences
between the way the two modeled the system. These included using a constant
probability of re-entrance rather than a constant one and using exponential service
times rather than the developed Gamma distributed times. The schedules generated
in this model proved to be unimodal under specific cost/weight structures in which
the system was stable. Under these stability conditions, schedules were produced and
those with the maximum profit function value were selected as the optimal schedules.
These schedules were then executed in the MMS clinic simulation. Results were
found to indicate that under most values of β, the scheduling policy outperformed
the current practice model. In the future, through the derivation of the expected profit
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from the algorithm, we hope to be able to develop a series of theorems describing the
function of our system so that we can better understand how it functions in all areas
of the previously mentioned parameter space.
With the development of these three tools, we believe that we have provided a
substantial framework for work in the future. This paper provides multiple areas
of research, including simulation, heuristic development, and algorithmic scheduling
policies. We believe that we have laid a basis that will enable these tools to be applied
rigorously in the future to Mohs Micrographic Surgery. MMS is a valuable tool in
the treatment of NMSCs, and we hope that with the development and application of
tools similar to those presented here, we can not only benefit the clinic’s operations,
but improve the overall patient experience.
6.2 Future Work
Beyond the imminent areas of future work mentioned previously, there are several
areas in which research of this nature can be continued. One of the major objectives
we would like to implement in the future is a sensitivity analysis of the performance of
our scheduling policy based on all of the parameters in the system, namely k, β,r,cw,
and co Such a sensitivity analysis will enable us to determine what parameters have
the most dramatic effect on the operation of our scheduling policy. This would then
allow a reformulation of the policy so as to combat any weakness.
Another area of development we would like to address is the current use of ex-
ponential service times. It is a common assumption due to its ease of calculation,
but often does not translate into real world application well. As such, we would like
to re-develop the model to account for general service times. This would allow this
study to be generalized to a wide range of applications.
An additional area of future work is into the utilization of service constraints,
as in Turkcan 2011 [34]. The application of service constraints to our system would
again improve the generalizability of study. As with the rest of this problem though,
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the difficulty arises in the re-entrant problem. Similarly, the inclusion of flexibility
in scheduling for personal preference would be an excellent addition to this study.
Patients do not typically simply accept whatever slot is assigned to them. They
usually have specific times they are available. This inclusion would definitely increase
the applicability and useful of this model in a real world setting.
Additionally we would like to change the implementation of the re-entrant prob-
ability in the scheduling policy. Currently, all patients in the system are assumed
to have the same β. This would not be the case in a real clinic. If we were able
to account for varying β values, such as Muthuraman accounts for varying no-show
probabilities [36], we could develop and test schedules under varying patient load
types. Additionally, allowing for varying β would enable a study of changing physi-
cian practices as well.
Finally, with the addition of some of the work mentioned above, implementation
would be the next logical step. In studies like this one, the eventual goal is always
implementation of your system in an actual clinic setting. We believe that with the
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